TNFRSF11A and neoplasm: In addition, tumors appear to be more sensitive to anti-programmed death ligand 1 (PD-L1) and/or anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) after inhibiting the RANK signaling pathway in tumor cells.